Effect of oral pseudoephedrine on blood pressure and heart rate: A meta-analysis

Archives of Internal Medicine

Volumn 165, Issue 15, 2005, Pages 1686-1694

  Salerno, Stephen M ^a   Jackson, Jeffrey L ^b   Berbano, Elizabeth P ^c  

^a TRIPLER ARMY MEDICAL CENTER   (United States)

^b UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^c WALTER REED ARMY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASTEMIZOLE; ATENOLOL; CLARITIN D; EPHEDRINE; IBUPROFEN; LINEZOLID; PLACEBO; PROPRANOLOL; PSEUDOEPHEDRINE;

ALLERGIC RHINITIS; ANXIETY DISORDER; ASTHMA; CLINICAL TRIAL; COMMON COLD; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG POTENTIATION; DRUG RELEASE; HUMAN; HYPERTENSION; PRIORITY JOURNAL; RANDOMIZATION; REVIEW; RHINITIS; RHINORRHEA; SEX DIFFERENCE; SINUS TACHYCARDIA; SYSTOLIC BLOOD PRESSURE; TACHYCARDIA;

BLOOD PRESSURE; DOSE-RESPONSE RELATIONSHIP, DRUG; EPHEDRINE; FEMALE; HEART RATE; HUMANS; MALE; SEX FACTORS; SYMPATHOMIMETICS;

EID: 23744491247     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.165.15.1686     Document Type: Review

References (40)

1. Physicians' Desk Reference. 57th ed. Montvale, NJ: Medical Economics Co; 2003.
2. Physicians' Desk Reference for Nonprescription Drugs and Dietary Supplements. 24th ed. Montvale, NJ: Medical Economics Co; 2003.
3. Pentel P. Toxicity of over-the-counter stimulants. JAMA. 1984;252:1898-1903.
4. Lake CR, Gallant S, Masson E, Miller P. Adverse drug effects attributed to phenylpropanolamine: a review of 142 case reports. Am J Med. 1990;89:195-208.
5. Radack K, Deck CC. Are oral decongestants safe in hypertension? an evaluation of the evidence and a framework for assessing clinical trials. Ann Allergy. 1986;56:396-401.
6. Morgan JP, Funderburk FR. Phenylpropanolamine and blood pressure: a review of prospective studies. Am J Clin Nutr. 1992;55(suppl):206S-210S.
7. US Food and Drug Administration. Center for Drug Evaluation and Research: phenylpropanolamine (PPA) information page . Available at: http://www .fda.gov/cder/drug/infopage/ppa/default.htm. Accessed December 15, 2003.
8. Cantu C, Arauz A, Murillo-Bonilla LM, Lopez M, Barinagarrementeria F. Stroke associated with sympathomimetics contained in over-the-counter cough and cold drugs. Stroke. 2003;34:1667-1672.
9. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17:1-12.
10. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629-634.
11. Galbraith RF. A note on graphical presentation of estimated odds ratios from several clinical trials. Stat Med. 1988;7:889-894.
12. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-188.
13. Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000;56:455-463.
14. Berkey CS, Hoaglin DC, Mosteller F, Colditz GA. A random-effects regression model for meta-analysis. Stat Med. 1995;14:395-411.
15. Backhouse CI, Rosenberg RM, Fidler C. Treatment of seasonal allergic rhinitis: a comparison of a combination tablet of terfenadine and pseudoephedrine with the individual ingredients. Br J Clin Pract. 1990;44:274-279.
16. Beck RA, Mercado DL, Seguin SM, Andrade WP, Cushner HM. Cardiovascular effects of pseudoephedrine in medically controlled hypertensive patients. Arch Intern Med. 1992;152:1242-1245.
17. Bradley JG, Kallail KJ, Dorsch JN, Fox J. The effects of pseudoephedrine on blood pressure in patients with controlled, uncomplicated hypertension: a randomized, double-blind, placebo-controlled trial. J Am Board Fam Pract. 1991;4:201-206.
18. Bright TP, Sandage BW Jr, Fletcher HP. Selected cardiac and metabolic responses to pseudoephedrine with exercise. J Clin Pharmacol. 1981;21:488-492.
19. Britton MG, Empey DW, John GC, McDonnell KA, Hughes DT. Histamine challenge and anterior nasal rhinometry: their use in the assessment of pseudoephedrine and triprolidine as nasal decongestants in subjects with hayfever. Br J Clin Pharmacol. 1978;6:51-58.
20. Bye C, Dewsbury D, Peck AW. Effects on the human central nervous system of two isomers of ephedrine and triprolidine, and their interaction. Br J Clin Pharmacol. 1974;1:71-78.
21. Bye C, Hill HM, Hughes DT, Peck AW. A comparison of plasma levels of L(+) pseudoephedrine following different formulations, and their relation to cardiovascular and subjective effects in man. Eur J Clin Pharmacol. 1975;8:47-53.
22. Chua SS, Benrimoj SI, Gordon RD, Williams G. A controlled clinical trial on the cardiovascular effects of single doses of pseudoephedrine in hypertensive patients. Br J Clin Pharmacol. 1989;28:369-372.
23. Clemons JM, Crosby SL. Cardiopulmonary and subjective effects of a 60 mg dose of pseudoephedrine on graded treadmill exercise. J Sports Med Phys Fitness. 1993;33:405-412.
24. Coates ML, Rembold CM, Farr BM. Does pseudoephedrine increase blood pressure in patients with controlled hypertension? J Fam Pract. 1995;40:22-26.
25. Dickerson J, Perrier D, Mayersohn M, Bressler R. Dose tolerance and pharmacokinetic studies of L (+) pseudoephedrine capsules in man. Eur J Clin Pharmacol. 1978;14:253-259.
26. Empey DW, Bye C, Hodder M, Hughes DTA. Double-blind crossover trial of pseudoephedrine and triprolidine, alone and in combination, for the treatment of allergenic rhinitis. Ann Allergy. 1975;34:41-46.
27. Henauer S, Seppey M, Huguenot C, Pecoud A. Effects of terfenadine and pseudoephedrine, alone and in combination in a nasal provocation test and in perennial rhinitis. Eur J Clin Pharmacol. 1991;41:321-324.
28. Hendershot PE, Antal EJ, Welshman IR, Batts DH, Hopkins NK. Linezolid: pharmacokinetic and pharmacodynamic evaluation of coadministration with pseudoephedrine HCl, phenylpropanolamine HCl, and dextromethorpan HBr. J Clin Pharmacol. 2001;41:563-572.
29. Janssens MM, Lins RL. Astemizole-D causes less sleep impairment than loratadine-D. J Int Med Res. 1995;23:167-174.
30. Laitinen LA, Empey DW, Bye C, Britton MG, McDonnell K, Hughes DT. A comparison of the bronchodilator action of pseudoephedrine and ephedrine in patients with reversible airway obstruction. Eur J Clin Pharmacol. 1982;23:107-109.
31. Mores N, Campia U, Navarra P, Cardillo C, Preziosi P. No cardiovascular effects of single-dose pseudoephedrine in patients with essential hypertension treated with β-blockers. Eur J Clin Pharmacol. 1999;55:251-254.
32. Negrini AC, Troise C, Voltolini S, Horak F, Bachert C, Janssens M. Oral antihistamine/decongestant treatment compared with intranasal corticosteroids in seasonal allergic rhinitis. Clin Exp Allergy. 1995;25:60-65.
33. Swain RA, Harsha DM, Baenziger J, Saywell RM Jr. Do pseudoephedrine or phenylpropanolamine improve maximum oxygen uptake and time to exhaustion? Clin J Sport Med. 1997;7:168-173.
34. Stroh JE Jr, Ayars GH, Bernstein IL, et al. A comparative tolerance study of terfenadine-pseudoephedrine combination tablets and pseudoephedrine tablets in patients with allergic or vasomotor rhinitis. J Int Med Res. 1988;16:420-427.
35. Sperber SJ, Sorrentino JV, Riker DK, Hayden FG. Evaluation of an alpha agonist alone and in combination with a nonsteroidal antiinflammatory agent in the treatment of experimental rhinovirus colds. Bull N Y Acad Med. 1989;65:145-160.
36. Rosene JM, Rosene JA, Koczajowski DL, Paolone VJ. Decongestant effects on hemodynamics at rest, exercise, and recovery from exercise during: 6 degrees of head down tilt. Aviat Space Environ Med. 1999;70:15-21.
37. Perkins JG, Bressler R, Heatherington D, Cato A, Dickerson J. A bioavailability and safety study comparing Actifed sustained-action (SA) capsules to Actifed immediate release (IR) tablets. Curr Ther Res. 1980;28:650-668.
38. Higgins EACW, McKenzie JM, Jennings AE, Funkhouser GE, Mullen SR. Effects of altitude and two decongestant-antihistamine preparations on physiological functions and performance. Aviat Space Environ Med. 1979;50:154-158.
39. Biaggioni I, Onrot J, Stewart CK, Robertson D. The potent pressor effect of phenylpropanolamine in patients with autonomic impairment. JAMA. 1987;258:236-239.
40. O'Connell MB, Pentel PR, Zimmerman CL. Individual variability in the blood pressure response to intravenous phenylpropanolamine: a pharmacokinetic and pharmacodynamic investigation. Clin Pharmacol Ther. 1989;45:252-259.